Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Orchestra BioMed Holdings, Inc. - Ordinary Shares
(NQ:
OBIO
)
4.590
+0.120 (+2.68%)
Streaming Delayed Price
Updated: 2:29 PM EDT, Apr 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Orchestra BioMed Holdings, Inc. - Ordinary Shares
< Previous
1
2
3
Next >
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
March 12, 2026
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
March 03, 2026
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
February 19, 2026
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2026
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
January 12, 2026
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
December 08, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 26, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
November 11, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
November 10, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Host Business Update Call on November 12, 2025
November 03, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
October 28, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
October 27, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
October 09, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
September 04, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
August 26, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
August 14, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
August 12, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
August 08, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
August 05, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces Pricing of $40 Million Public Offering
August 01, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces Proposed Public Offering
July 31, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
July 31, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
June 18, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Sidoti Events, LLC's Virtual May Micro-Cap Conference
May 20, 2025
Via
ACCESS Newswire
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
May 12, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
May 07, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
April 29, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
April 28, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
April 23, 2025
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
SmallCaps Gaining Momentum: TIVC, GELS, SLI, OBIO in Healthcare, Biotech, Energy, Military Defense, Etc. – More Stocks Inside
April 22, 2025
Via
AB Newswire
Topics
Government
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
